Category:

Cardiff Oncology (CRDF) – FY2025 Reported With Onvansertib Phase 2b Data Review

Posted on by slightbourne@noblecapitalmarkets.com


Thursday, February 26, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FY2026 Reported With Onvansertib Review. Cardiff reported a FY2025 loss of $45.8 million or $(0.69) per share and reviewed the clinical data for onvansertib, its drug for RAS-mutated metastatic colorectal cancer (mCRC). Updated plans for Phase 3 are expected after discussions with the FDA during 1H26. On December 31, 2025, Cardiff ended the year with $58.3 million in cash and equivalents, which it believes can fund operations through 1Q27.

Phase 2 CRDF-004 Trial Design. The CDRF-004 Phase 2 trial was designed to test two doses of onvansertib in combination with two standard-of-care (SOC) regimens against each standard of care regimen alone. It enrolled 110 patients with RAS-mutated mCRC. The primary endpoint was objective response rate (ORR).


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Google Updates Viral AI Image Tool With Faster, Smarter Nano Banana 2

Posted on by slightbourne@noblecapitalmarkets.com

Google is doubling down on generative AI with the launch of Nano Banana 2, the latest version of its viral AI image generator. The update, announced Thursday, is designed to make the tool faster, more precise and better at rendering text — a key improvement for use cases such as marketing mockups, greeting cards and branded visuals. The rollout underscores how aggressively large technology platforms are iterating in the increasingly competitive AI image and video market.

Shares of Alphabet traded lower alongside the broader tech market, but the Nano Banana refresh highlights the company’s continued push to integrate generative AI deeper into its Gemini ecosystem.

Nano Banana first launched in August and quickly gained traction online as users shared AI-generated images across social platforms. Google followed with Nano Banana Pro in November, built on Gemini 3 Pro, targeting higher-fidelity and more accuracy-sensitive use cases.

Nano Banana 2 is now positioned as the speed-optimized successor.

According to Google, the new model incorporates “advanced world knowledge,” pulling real-time information from Gemini to produce more accurate visual renderings. The company emphasized three primary upgrades: faster generation, improved instruction-following and more precise text rendering inside images — an area where AI image models have historically struggled.

While Nano Banana Pro will remain available for high-fidelity tasks requiring maximum factual precision, Nano Banana 2 is being positioned for rapid creation and integrated image-search grounding. The new version will replace its predecessor across Gemini’s Fast, Thinking and Pro tiers.

The move comes as AI image and video tools are becoming mainstream consumer products. Users can now generate increasingly sophisticated visuals from simple text prompts, blurring the line between professional and consumer-grade creative tools.

Competition in the space is intensifying.

OpenAI launched its video-generation model Sora in 2024, drawing massive demand. Adobe has continued expanding Firefly, integrating generative AI across its creative software suite. ByteDance has also introduced its Seedance video-generation tool, though it has faced legal scrutiny from major studios over alleged intellectual property violations.

The rapid adoption of AI creative tools has also fueled debate around copyright, training data and the protection of original content. Media and entertainment companies have raised concerns that generative models may infringe on protected works, increasing regulatory and legal uncertainty across the sector.

For investors, Google’s Nano Banana 2 rollout highlights a broader capital allocation theme in 2026: speed of iteration is becoming a competitive advantage in AI.

Large platforms are not only investing heavily in infrastructure — such as GPUs and data centers — but are also racing to deliver user-facing AI products that drive engagement, subscription upgrades and enterprise adoption.

The generative AI market is still in its early innings. However, with major players rolling out new versions in rapid succession, product cycles are shortening, and differentiation is increasingly tied to performance, reliability and integration with broader ecosystems.

Nano Banana 2 may be an incremental upgrade. But in today’s AI arms race, incremental improvements — delivered quickly — can shape market leadership.

Biotech’s 2026 Capital Window: Why Clinical-Stage Companies Are Preparing Now

Posted on by slightbourne@noblecapitalmarkets.com

Clinical development is inherently capital intensive. As programs move from early-stage studies into Phase 2 and Phase 3 trials, costs typically rise due to expanded enrollment, multi-site coordination, manufacturing scale-up, and regulatory preparation.

Companies such as Eledon Pharmaceuticals, which is advancing immune-modulating therapies, and Cardiff Oncology, focused on targeted oncology treatments including onvansertib, illustrate the type of clinical-stage businesses navigating these funding dynamics. As programs mature, capital planning becomes increasingly tied to milestone timing.

Similarly, Ocugen, with gene therapy and ophthalmology-focused programs, and Cocrystal Pharma, which develops antiviral therapeutics, operate in segments where development timelines and regulatory pathways can require sustained financial flexibility.

Even companies earlier in commercialization strategy development, such as Nutriband, which is advancing transdermal pharmaceutical technologies, must balance product advancement with capital market realities.

These examples reflect a broader sector pattern: advancing innovation requires consistent access to funding.

The Importance of the Catalyst Calendar

Biotech financing windows often open around meaningful clinical or regulatory catalysts. Positive data can strengthen negotiating leverage. But waiting until after results are announced can introduce risk — particularly if broader market conditions shift.

With 2026 shaping up to include a number of anticipated data readouts across the industry, companies are evaluating whether to raise capital ahead of milestones, opportunistically during periods of sector strength, or in response to results.

Preparation matters.

Management teams that establish investor visibility and maintain consistent communication before catalysts emerge may find themselves better positioned if and when market windows open.

M&A Activity Is a Tailwind — Not a Strategy

Large pharmaceutical companies continue to evaluate external pipelines to supplement internal research efforts. Periodic acquisition activity can improve sentiment across small-cap biotech and help reset valuation benchmarks.

However, M&A remains selective and unpredictable. Most clinical-stage companies must plan under the assumption that equity or structured financing will remain the primary funding path.

For investors, that distinction is important.

Why Capital Strategy Matters for Shareholders

In small-cap biotech, capital access influences more than just cash runway. It can affect development pace, trial continuity, partnership leverage, and dilution levels.

A company that secures funding under stable market conditions may retain greater operational flexibility. One that is forced to raise under pressure may encounter less favorable terms.

As 2026 approaches, the differentiator may not simply be who generates data — but who manages capital strategy effectively alongside clinical execution.

Biotech remains data-driven and inherently volatile. Yet improving sector sentiment and a growing milestone calendar suggest that capital formation decisions could play a defining role in shaping outcomes over the next 12–18 months.

For small-cap investors, understanding both the science and the financing strategy may be equally important in the year ahead.

Release – The Beachbody Company, Inc. Announces Fourth Quarter 2025 Earnings Release Date, Conference Call, and Webcast

Posted on by aweinsoff@channelchek.com

Research News and Market Data on BODI

February 25, 2026

EL SEGUNDO, Calif.–(BUSINESS WIRE)– The Beachbody Company, Inc. (NASDAQ: BODI) (“BODi” or the “Company”), a leading fitness and nutrition company, will release its fourth quarter 2025 results on Tuesday, March 10, 2026, after the U.S. stock market closes. The Company will host a conference call at 5:00 p.m. (Eastern Time) that day to discuss the results.

The toll-free dial-in for the conference call is (833) 470-1428 (U.S. & Canada), or click here for Global Dial-In Numbers. The conference ID is 871093. A live webcast of the conference call will also be available on the Company’s investor relations website at https://investors.thebeachbodycompany.com/.

For those unable to participate in the conference call, a replay will be available after the conclusion of the call on March 10, 2026, through March 17, 2026. The toll-free replay dial-in number is (866) 813-9403 (U.S & Canada). The replay passcode is 989620.

About BODi and The Beachbody Company, Inc.

BODi, formerly known as Beachbody, has been a pioneer in structured, step-by-step home fitness and nutrition programs for nearly three decades, with iconic products such as P90X, INSANITY, 21 Day Fix and the original premium superfood nutrition supplement, Shakeology. Since its inception, BODi has helped more than 30 million people reach life-changing results. Today, BODi continues to evolve with a simple mission: help people achieve their goals and lead healthier, more fulfilling lives, especially busy, time-strapped people who want to fit healthy habits into everyday life with proven solutions. The BODi community empowers millions to stay motivated and accountable, supporting healthy weight management, improved metabolic function, increased mental and physical well-being, better sleep, as well as evidence-based habits that enhance healthspan and longevity.

To subscribe and shop, visit BODi.com. For company and investor information, please visit TheBeachbodyCompany.com.

Investor Relations
IR@BODi.com

Source: The Beachbody Company, Inc.

Release – Zomedica Expands Distribution of TRUVIEW(R) Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary Pathology

Posted on by slightbourne@noblecapitalmarkets.com

Partnership Expected to Accelerate System Placements and Support Recurring Consumables Revenue Growth

ANN ARBOR, MI / ACCESS Newswire / February 25, 2026 / Zomedica Corp. (OTCQB:ZOMDF) (“Zomedica” or the “Company”), an animal health company offering innovative diagnostic and therapeutic products for equine and companion animals, today announced a commercial distribution agreement with Moichor, a recognized leader in veterinary reference and point-of-care laboratory services across the United States.

Under the agreement, in addition to Zomedica’s own direct placements of TRUVIEW systems in the United States, it will also supply its TRUVIEW digital microscopy systems and associated testing supplies for Moichor’s sale to its point-of-care veterinary customers nationwide. The systems will be co-branded and integrated with Moichor’s proprietary AI engine and board-certified pathology services to support rapid, accurate clinical decision-making in veterinary practices.

Moichor is widely regarded for its expertise in both canine and feline diagnostic services and has established leadership in the exotic animal segment, with placements in numerous exotic veterinary practices throughout the United States. This agreement expands the TRUVIEW platform’s reach into both traditional companion animal practices and specialized exotic animal hospitals.

Each TRUVIEW system placement drives demand for proprietary testing materials and consumables supplied by Zomedica. As systems are adopted across Moichor’s customer base, the Company expects to generate recurring revenue tied to diagnostic utilization.

“Partnering with Moichor represents a meaningful step forward in expanding the commercial footprint of the TRUVIEW microscope,” said Bill Campbell, Zomedica’s Vice President, Imaging. “Moichor’s reputation for pathology excellence and its growing presence in both companion and exotic animal medicine align perfectly with our mission to deliver accessible, high-quality diagnostic solutions at the point of care. By combining digital slide preparation, high-resolution imaging, and integrated pathology support, we are helping practices modernize cytology workflows while maintaining diagnostic confidence.”

Expanding Access to AI-Enhanced Digital Cytology

The TRUVIEW® platform is designed to modernize in-clinic cytology by enabling automated slide preparation and high-resolution digital imaging that can be reviewed locally or shared remotely. Consistent, standardized slide preparation is a critical component of accurate cytologic interpretation. By automating this process, the TRUVIEW system helps reduce variability between samples, minimize the occurrence of unreadable or suboptimal slides, and improve overall diagnostic confidence.

Through this agreement, veterinary customers will utilize Moichor’s proprietary AI engine in combination with its pathology services to help ensure rapid and accurate diagnoses.

By combining TRUVIEW digital microscopy capabilities with Moichor’s AI-enabled workflow and pathology expertise, practices can:

  • Improve diagnostic turnaround times
  • Increase confidence in cytology interpretation
  • Leverage the TRUVIEW microscope’s automated slide preparation to reduce unreadable slides and improve consistency of pathology interpretation
  • Enhance collaboration between in-clinic teams and pathology specialists
  • Deliver improved patient care across canine, feline, and exotic species

“We are excited to partner with Zomedica to expand access to advanced digital cytology solutions,” said Joe Faiella, CEO of at Moichor. “The integration of the TRUVIEW platform with our proprietary AI engine and pathology services allows us to provide veterinarians with a seamless, technology-enabled diagnostic experience. Together, we are strengthening point-of-care capabilities while maintaining the high standards of accuracy and service our customers expect.”

The co-branded systems will support Moichor’s expanding point-of-care strategy, allowing practices to integrate advanced digital cytology into their existing workflows while maintaining access to expert pathology oversight.

Strengthening Zomedica’s Recurring Revenue Model

From a strategic perspective, this commercial agreement is expected to contribute to both capital equipment sales and ongoing consumables revenue. As TRUVIEW systems are deployed through Moichor’s customer network, Zomedica will supply the associated consumables, supporting a scalable, recurring revenue stream tied to diagnostic utilization.

“This agreement reflects our disciplined approach to expanding distribution through partners who bring strong clinical credibility and national reach,” said Larry Heaton, Chief Executive Officer of Zomedica. “By integrating Zomedica’s TRUVIEW platform with Moichor’s AI engine and pathology services, we are enhancing the value proposition for veterinarians while strengthening our long-term growth trajectory. We believe that partnerships like this allow us to accelerate adoption, increase recurring revenue, and deliver sustainable value for our shareholders.”

Supporting Innovation in Veterinary Diagnostics

The veterinary diagnostics market continues to evolve as practices seek faster, technology-enabled tools that improve clinical efficiency and elevate standards of care. Digital imaging, artificial intelligence, and remote pathology integration are increasingly shaping the future of in-clinic laboratory services.

Through this agreement, Zomedica and Moichor aim to deliver a comprehensive, technology-driven cytology solution that empowers veterinarians to make informed decisions with speed and confidence-ultimately benefiting both patients and pet owners.

About Zomedica

Zomedica is a leading equine and companion animal health company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® line of therapeutic devices, the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VETGuardian® PLUS™Zero Touch™ monitoring system, and Vetigel® hemostatic gel, a revolutionary hemostatic agent that rapidly stops bleeding, each designed to empower veterinarians to deliver top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $54.4 million in liquidity as of September 30, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

Investor Relations Contact:

Zomedica Investor Relations
Investors@zomedica.com
1-734-369-2555

SOURCE: Zomedica Corp.

Release – Kratos Awarded $61.1 Million Navy Contract Modification for Full-Rate Production of 70 BQM-177A Subsonic Aerial Targets and Equipment

Posted on by slightbourne@noblecapitalmarkets.com

February 25, 2026

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a leader in defense, national security and global markets, announced today that it has been awarded a $61,068,139 modification to a previously awarded firm-fixed-price contract (N0001923C0021) by the U.S. Navy. This contract modification exercises options to procure full-rate production Lot Seven for 70 of the BQM-177A Subsonic Aerial Targets, along with 70 Rocket-Assisted Takeoff (RATO) attachment kits and associated technical and administrative data. The systems will support weapons system test and evaluation and fleet training requirements for the U.S. Navy.

“Achieving full-rate production of the BQM-177A reflects the Navy’s continued confidence in Kratos’ ability to deliver reliable, high-performance aerial target systems at scale,” said Steve Fendley, President of Kratos Unmanned Systems Division. “This award underscores our commitment to providing affordable, mission-relevant unmanned systems that directly support Navy training, test, and evaluation requirements while maintaining production readiness for future demand. As with all previous awards or modifications, the exercise of this final option is at the maximum negotiated production quantity of seventy aircraft resulting in a total contract value of $238,798,157. In anticipation of further full rate production contracts, Kratos is continuing to invest in capital production improvements that will further improve either our capacity or efficiency.”

The BQM-177A is a subsonic, surface-launched aerial target designed to support realistic threat representation for advanced weapons testing and fleet training operations.

Work under the contract is expected to be performed in the following locations (with the expected share of the work): Sacramento, California (50%); Dallas, Texas (20%); Fort Walton Beach, Florida (5%); Blacksburg, Virginia (4%); Santa Ana, California (2%); Newton, Kansas (2%); Concord, California (2%); Milwaukie, Oregon (2%); Chatsworth, California (2%); and various other locations within the continental United States (11%). The contract is expected to be completed in August 2028.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, advanced vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Release – First Phosphate Announces American Depositary Receipt Program Under Ticker Symbol FPHOY

Posted on by slightbourne@noblecapitalmarkets.com

Saguenay, Quebec–(Newsfile Corp. – February 25, 2026) – First Phosphate Corp. (CSE: PHOS) (OTCQX: FRSPF) (OTCQX ADR: FPHOY) (FSE: KD0) (“First Phosphate” or the “Company“) is pleased to announce the launch of its sponsored Level 1 American Depositary Receipt (“ADR“) program to increase exposure to American and international investors wishing direct access to Quebec igneous phosphate and the downstream lithium iron phosphate (“LFP“) battery supply chain.

The First Phosphate ADR is now available for trading in the United States on the OTCQX market under the symbol “FPHOY” (CUSIP: 33611D301; ISIN: US33611D3017).

The First Phosphate ADR is the first Canadian Level 1 company-sponsored ADR to trade on OTC Markets. The ADR ratio is set to ten (10) First Phosphate common shares for each (1) First Phosphate ADR.

Participants may issue ADRs at no cost during the first 6 months after the effectiveness date of the program (February 12, 2026) through The Bank of New York Mellon (“BNY“) which has been appointed as depositary bank for the First Phosphate ADR program.

The new First Phosphate ADR is complimentary to all other Company listings on all other stock exchanges and does not affect the Company’s current OTCQX listed common shares under symbol “FRSPF“.

BNY facilitates the issuance and cancellation of First Phosphate ADRs in accordance with instructions received from market participants. The First Phosphate ADR program operates in accordance with a deposit agreement, filed with the United States Securities and Exchange Commission (“SEC“) and available through https://www.sec.gov/Archives/edgar/data/2108542/000101915526000028/0001019155-26-000028-index.htm. The First Phosphate common shares underlying the First Phosphate ADRs are held in custody by BNY.

The establishment of the First Phosphate ADR program is not a new offering of securities and, therefore, no additional shares are being issued nor is any capital being raised in connection with the launch of the First Phosphate ADR program. Moreover, nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

An ADR is a separate security denominated in US dollars that allows US investors to invest in shares of non-US companies without the need for cross-border or cross-currency transactions.

Initial Payment Received Under Long-term Offtake Agreement

The Company has now received the initial payment of USD $523,017.59 in respect of the existing, long-term phosphate concentrate offtake agreement with its existing offtake partner as announced on January 6, 2026 (https://firstphosphate.com/offtakepayment).

Options Exercise & RSU Grants

Z Six Financial Corporation, an entity controlled by Laurence W. Zeifman, Chaiman of the Board of First Phosphate, has exercised 300,000 options originally issued on September 14, 2022 and exercisable at $0.25 and 300,000 options originally issued on December 22, 2022 and exercisable at $0.35 per option.

Pursuant to an exemption granted by the Canadian Securities Exchange to Policy 6.5(7), the Company has issued 781,395 Restricted Share Units (“RSUs“) to ExpoWorld Ltd. (“ExpoWorld“), an entity controlled by John Passalacqua, CEO of First Phosphate, as consideration for the termination of 1,200,000 options held by ExpoWorld including 600,000 options originally issued on September 14, 2022 and exercisable at $0.25 per option, and 600,000 options originally issued on December 22, 2022 and exercisable at $0.35 per option (the “Options“). These vested RSUs represent the in-the-money value of the Options being terminated (calculated based on the closing price of First Phosphate shares on February 10, 2026) and serve to facilitate the cashless exercise of options while minimizing the impact that the transaction would have on the open market.

The Company also informs that Mr. Passalacqua, through ExpoWorld, made an open market purchase of 119,500 shares in the open market on January 30, 2026.

As a show of commitment to the business and alignment with shareholders, the Board and management will receive approximately 50% of their total compensation in the form of RSUs. As such, the Board has approved the grant of 1,975,000 RSUs to eligible directors, officers, consultants and employees of the Company for services to be provided for the 12-month period commencing March 1, 2026. One-half of these new RSUs will vest on August 31, 2026 and February 28, 2027, respectively. All of the common shares issuable on vesting of the RSUs will be subject to a hold period of four months plus one day from the date of vesting. The RSUs will be granted in accordance with and subject to the Company’s Omnibus Equity Incentive Plan.

About First Phosphate Corp.

First Phosphate (CSE: PHOS) (OTCQX: FRSPF) (OTCQX ADR: FPHOY) (FSE: KD0) is a mineral exploration, development and cleantech company dedicated to examining and ultimately building and onshoring a vertically integrated mine-to-market lithium iron phosphate (LFP) battery supply chain for North America. Target markets include energy storage, data centers, robotics, mobility and national security.

First Phosphate’s flagship Bégin-Lamarche Property in Saguenay–Lac-Saint-Jean, Quebec, Canada is a North American rare igneous phosphate resource yielding high-purity phosphate with minimal impurities.

Media & Investor Contact:

Bennett Kurtz
Chief Financial Officer
bennett@firstphosphate.com
Tel: +1 (416) 200-0657

Investor Relations: investor@firstphosphate.com
Media Relations: media@firstphosphate.com
Website: www.FirstPhosphate.com

Cadrenal Therapeutics (CVKD) – CAD-1005 Phase 2 Results Announced, With FDA Guidance Meeting Scheduled

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, February 25, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Cadrenal Announced Phase 2 Data With End-of-Phase-2 Meeting Scheduled. Cadrenal announced data from the Phase 2 trial of its anti-thrombotic CAD-1005 (formerly known as VLX-1005) for HIT, or heparin-induced thrombocytopenia. Cadrenal has also been granted an End-of-Phase 2 meeting with the FDA to discuss the trial results and design of a Phase 3 trial. These are important milestones in the development of CAD-1005.

Phase 2 Produced Unexpected Findings. The Phase 2 trial tested safety and efficacy of CAD-1005 in patients receiving standard anticoagulant therapy. Its Primary Endpoint was designed to show CAD-1005 improved platelet recovery, testing platelet count recovery as a biomarker for thrombosis and outcome. This Primary Endpoint did not meet statistical significance, and did not find a correlation between platelet count normalization and thrombotic events.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

V2X (VVX) – A Strong End to the Year

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, February 25, 2026

V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. In the fourth quarter, V2X drove record quarterly revenue, adjusted EBITDA, and adjusted cash flow. These results reflect the strength of the Company’s strategy and alignment with national security priorities for readiness and modernization. V2X continues to see momentum across the business coming through contract wins in key growth areas, and we are encouraged by the ongoing demand for the Company’s mission solutions.

4Q25 Results. Revenue increased 5% y-o-y to a record $1.22 billion.  Adjusted EBITDA was $88.7 million for the quarter, also a record for the Company. and exceeding management’s expectations. Adjusted net income was $49.3 million and adjusted EPS was $1.56, both representing double-digit year-over-year growth. We were at $1.19 billion, $81 million, and $1.33, respectively.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Perfect (PERF) – Revenue Growth Story Intact

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, February 25, 2026

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q4 results. Perfect reported Q4 revenue of $18.1 million, up 14.2% Y/Y and largely in line with our estimate of $18.2 million, while adj. EBITDA of $1.4 million exceeded our forecast of $1.0 million, representing 8% margins. Excluding a one-time goodwill write-off, the company would have generated operating income, underscoring improving cost discipline and operating leverage.

B2C momentum the primary growth driver. Management noted that strong demand for AI-powered content creation is driving engagement across the YouCam app portfolio. Generative AI photo and video tools remain key contributors, and we believe Perfect’s expertise with these technologies positions it well to benefit from sustained demand for personalized, AI-enabled digital experiences.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

InPlay Oil (IPOOF) – 2026 Guidance Points to Disciplined Growth and Continued Deleveraging

Posted on by slightbourne@noblecapitalmarkets.com


Wednesday, February 25, 2026

InPlay Oil is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQX Exchange under the symbol IPOOF.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2026 guidance. InPlay approved a C$66 to C$74 million capital program targeting average production of 18,600 to 19,200 boe/d (~61% light oil and NGLs), representing approximately 11% growth over the estimated 2025 production of ~17,000 boe/d. Management forecasts adjusted funds flow (AFF) of C$122 to C$129 million and free adjusted funds flow (FAFF) of C$48 to C$63 million, implying an 11% to 15% FAFF yield. Year-end net debt is guided to C$199 to C$206 million, reflecting continued deleveraging.

Estimate revisions. We have adjusted our 2026 estimates to average production of 18,900 boe/d, revenue of C$338.3 million, and AFF of C$125.2 million, or C$4.45 per share. For Q1 2026, we have assumed production of 18,605 boe/d, revenue of C$79.0 million, and AFF of C$26.6 million, or C$0.95 per share. The first quarter carries heavier drilling activity, with five wells drilled and completed, most coming onstream late in the period, marking Q1 as the lightest production quarter of the year. We forecast 2026 capital expenditures of C$70 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Housing Stocks Slide as Policy Hopes Fade and Outlooks Darken

Posted on by slightbourne@noblecapitalmarkets.com

Housing-linked equities took a sharp hit Wednesday, pressured by cautious corporate outlooks and the absence of new housing initiatives in President Donald Trump’s State of the Union address.

The S&P Composite Homebuilders Index dropped as much as 5.2%, marking its steepest decline since last April’s tariff-driven selloff. The retreat swept across builders, suppliers, and mortgage-related names, underscoring just how sensitive the group remains to policy signals and macro sentiment.

Among the hardest hit were Green Brick Partners, Lennar, Champion Homes, Dream Finders Homes, Installed Building Products, D.R. Horton, and TopBuild. Mortgage-exposed firms such as Rocket Cos. also traded lower as investors reassessed the near-term demand outlook.

The pullback followed a subdued forecast from Lowe’s Cos., which projected full-year sales below Wall Street expectations. Shares of the home improvement retailer fell more than 5% intraday. The guidance came on the heels of cautious commentary from Home Depot, reinforcing concerns that housing-related spending may remain muted in 2026.

For investors, the message was clear: the housing market is still searching for a catalyst.

Executives pointed to persistent affordability challenges, elevated mortgage rates, and broader economic uncertainty. Lowe’s Chief Executive Marvin Ellison cited inflationary pressures and subdued consumer confidence. He also highlighted the ongoing “lock-in effect,” where homeowners are reluctant to sell because they would need to refinance at significantly higher mortgage rates.

Home Depot’s finance chief echoed similar themes earlier in the week, noting that while homeowners remain relatively healthy financially, uncertainty around affordability and employment is weighing on decision-making.

Expectations had been building that the administration might unveil fresh housing initiatives. Instead, the president largely reiterated previous comments about potentially restricting institutional investors from purchasing single-family homes and suggested that lower interest rates would ultimately address affordability concerns. Broader housing policy proposals were absent.

That lack of clarity appeared to disappoint investors who had hoped for targeted measures to stimulate supply or ease affordability pressures.

The selloff extended beyond homebuilders. The S&P Composite 1500 Building Products Index fell as much as 2.5%, with companies such as Hayward Holdings, UFP Industries, and Builders FirstSource among the largest percentage decliners.

For small- and mid-cap investors, the volatility highlights how exposed housing-related equities remain to macro swings. Many regional builders and specialty suppliers operate with narrower margins and less diversified revenue streams than large-cap peers. That makes them particularly sensitive to changes in mortgage rates, input costs, and consumer confidence.

At the same time, prolonged weakness in transaction volumes can ripple across the ecosystem — from building products manufacturers to installation services and mortgage originators. When turnover slows, renovation activity, new construction starts, and related spending often follow.

The broader question for 2026 is whether easing financial conditions materialize quickly enough to offset affordability headwinds. While policymakers and corporate executives continue to point to the potential for rate relief, timing remains uncertain.

Until clearer signals emerge — either from monetary policy, fiscal initiatives, or a sustained improvement in housing demand — the sector may continue to trade on headlines rather than fundamentals.

For investors in small- and middle-market housing names, that likely means heightened volatility, selective capital flows, and a continued premium on balance sheet strength.

Release – CVG Announces Fourth Quarter and Full Year 2025 Earnings Call

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CVGI

February 24, 2026

NEW ALBANY, Ohio, Feb. 24, 2026 (GLOBE NEWSWIRE) — Commercial Vehicle Group (the “Company” or “CVG”) (NASDAQ: CVGI) will hold its quarterly conference call on Wednesday, March 11, 2026, at 8:30 a.m. ET, to discuss fourth quarter and full year 2025 financial results. CVG will issue a press release and presentation prior to the conference call.

Toll-free participants dial (800) 549-8228 using conference code 51917. International participants dial (289) 819-1520 using conference code 51917. This call is being webcast and can be accessed through the “Investors” section of CVG’s website at ir.cvgrp.com where it will be archived for one year.

A telephonic replay of the conference call will be available until March 25, 2026. To access the replay, toll-free callers can dial (+1) 888 660 6264 using access code 51917 #, and toll callers in North America and other locations can dial (+1) 289 819 1325.

About CVG

At CVG, we deliver real solutions to complex design, engineering and manufacturing problems while creating positive change for our customers, industries, and communities we serve. Information about the Company and its products is available on the internet at www.cvgrp.com.

Investor Relations Contact:
Ross Collins or Nathan Skown
Alpha IR Group
CVGI@alpha-ir.com

Primary Logo

Source: Commercial Vehicle Group, Inc.